NCT06205602 (ACACIA) is a Phase 2 clinical trial of 3BNC117-LS in HIV-1-infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

What drugs are being tested in NCT06205602?

Interventions in NCT06205602: 3BNC117-LS, 10-1074-LS, Placebo for 3BNC117-LS, Placebo for 10-1074-LS.

What condition does NCT06205602 study?

NCT06205602 studies HIV-1-infection.

Is NCT06205602 still recruiting?

NCT06205602 is currently recruiting now. Last updated 31 January 2025.

Last reviewed 2025-01-31 · How we verify

NCT06205602: ACACIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Recruiting now Phase 2 Last updated 31 January 2025

What this trial tests

Phase 2 trial testing 3BNC117-LS in HIV-1-infection in 135 participants. Currently enrolling.

Timeline

17 January 2025

Primary endpoint
16 February 2029

16 February 2029

Quick facts

Lead sponsor	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	135
Start date	17 January 2025
Primary completion	16 February 2029
Estimated completion	16 February 2029
Sites	4 locations across Botswana, South Africa

Drugs / interventions tested

3BNC117-LS — full drug profile →
10-1074-LS — full drug profile →
Placebo for 3BNC117-LS — full drug profile →
Placebo for 10-1074-LS — full drug profile →

Conditions studied

HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Who can join

Adults 18 to 60, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular tests. HIV is also hidden in cells throughout the body and can start multiplying when ART is stopped. This research study will test two new study drugs: 10-1074-LS and 3BNC117-LS. Both of these study drugs are antibodies against HIV. An antibody is generally a substance that the body makes in response to an infection. The antibodies being used in this study were made in a laboratory and were designed to attach to HIV and can block HIV from attacking cells in the body and from spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV. The main purpose of this study is to see if the study drugs affect the level of HIV that remains in the blood cells while taking ART and the level of HIV in the blood after discontinuing taking ART. The study will also see if it is safe to give people these antibodies and if they cause any side effects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.
Mahomed S, Pillay K, Hassan-Moosa R, Galvão BPGV, et al · · 2025 · cited 20× · PMID 40189566 · DOI 10.1186/s12981-025-00734-8
Correlates of HIV-1 control after combination immunotherapy.
Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, et al · · 2026 · cited 15× · PMID 41326736 · DOI 10.1038/s41586-025-09929-5

Verify or expand the search:

Other trials of 3BNC117-LS

Trials testing the same drug.

NCT05079451 — Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI · Phase 1 · withdrawn
NCT05612178 — A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs · Phase 1 · active not recruiting
NCT05245292 — 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) · Phase 1 · completed
NCT04250636 — 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals · Phase 1 · completed
NCT03554408 — First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS · Phase 1 · completed

Other recruiting trials for HIV-1-infection

Currently open trials in the same condition.

NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting

Other Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections trials

Trials by the same sponsor.

NCT06205589 — Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB · Phase 2 · not yet recruiting
NCT06856174 — Menopausal HT for Women Living With HIV (HoT) · Phase 4 · not yet recruiting
NCT06031272 — Pausing Antiretroviral Treatment Under Structured Evaluation · Phase 1 · active not recruiting
NCT05985642 — Observational PIC Destination Cohort · recruiting
NCT05156658 — Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06205602 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06205602.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing